Patient Group	Patients treated with anti‐C5 monotherapy (n = 17)	Patients treated with C5 inhibitor and indefinite anticoagulation (n = 4)
Diagnosis Classical PNH PNH/AA	10 7	4 ‐
Sex Male Female	10 7	1 3
Median age of diagnosis (range)	24 years (10–59)	41 years (36–61)
Median granulocyte clone (range)	97% (73–100)	87% (78–99)
Median time prior to anti‐C5 treatment (range)	5 years (1–14)	3.5 years (1–8)
Median time on anti‐C5 treatment (range)	10 years (0.5–14)	9.5 years (5–13)
Median time on anticoagulation (range)	1 month (0–11 years)	9 years (5–19)
Location of TE pre‐C5 inhibitor DVT pulmonary embolism abdominal vein dermal small bowel cerebrovascular inferior vena cava renal vein ureter tonsillar	1 2 9 1 3 3 1 2 1 1	1 1 2 ‐ ‐ 2 ‐ ‐ ‐ ‐
Location TE on C5 inhibitor DVT pulmonary embolism	2 ‐	1 1